Desmopressin (DDAVP) serves as a therapeutic agent in type 1 von Willebrand disease (vWD) by promoting the endogenous release of vWF from endothelial cell stores, thereby transiently augmenting plasma vWF and factor VIII levels [46]. This evidence concerns the gene VWF and Von Willebrand disease.